Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMT NASDAQ:SNDX NASDAQ:SRPT NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$8.97+1.4%$9.48$3.42▼$12.34$468.95M2.77734,519 shs279,721 shsSNDXSyndax Pharmaceuticals$19.75+0.7%$22.40$8.59▼$25.59$1.75B0.411.45 million shs1.02 million shsSRPTSarepta Therapeutics$17.30+3.7%$19.99$10.41▼$43.92$1.83B0.262.92 million shs2.93 million shsVCELVericel$34.24-0.1%$33.86$28.95▼$45.97$1.75B1.15597,206 shs397,009 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics+1.61%+4.49%-6.35%-8.39%+158.77%SNDXSyndax Pharmaceuticals-1.46%-2.58%-6.62%-5.13%+97.48%SRPTSarepta Therapeutics+0.06%-2.57%-20.50%-4.41%-56.51%VCELVericel-2.00%-3.19%-7.18%-9.05%-18.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$8.97+1.4%$9.48$3.42▼$12.34$468.95M2.77734,519 shs279,721 shsSNDXSyndax Pharmaceuticals$19.75+0.7%$22.40$8.59▼$25.59$1.75B0.411.45 million shs1.02 million shsSRPTSarepta Therapeutics$17.30+3.7%$19.99$10.41▼$43.92$1.83B0.262.92 million shs2.93 million shsVCELVericel$34.24-0.1%$33.86$28.95▼$45.97$1.75B1.15597,206 shs397,009 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics+1.61%+4.49%-6.35%-8.39%+158.77%SNDXSyndax Pharmaceuticals-1.46%-2.58%-6.62%-5.13%+97.48%SRPTSarepta Therapeutics+0.06%-2.57%-20.50%-4.41%-56.51%VCELVericel-2.00%-3.19%-7.18%-9.05%-18.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.67Moderate Buy$29.88232.35% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55119.65% UpsideSRPTSarepta Therapeutics 2.11Hold$27.1758.03% UpsideVCELVericel 2.50Moderate Buy$55.4063.16% UpsideCurrent Analyst Ratings BreakdownLatest FDMT, SRPT, VCEL, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/22/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/13/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $37.005/11/2026VCELVericel Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/8/2026FDMT4D Molecular Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/8/2026VCELVericel HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.005/1/2026SNDXSyndax Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.004/22/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/20/2026FDMT4D Molecular Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$85.21M5.52N/AN/A$8.64 per share1.04SNDXSyndax Pharmaceuticals$172.35M9.96N/AN/A$0.47 per share41.21SRPTSarepta Therapeutics$2.18B0.83N/AN/A$14.26 per share1.21VCELVericel$292.09M5.94$0.54 per share62.95$6.98 per share4.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$140.11M-$2.57N/AN/AN/A-182.34%-36.83%-32.55%8/10/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A7.510.19-2.94%7.56%2.94%8/5/2026 (Estimated)VCELVericel$16.52M$0.4280.7440.91N/A7.35%6.41%4.61%7/30/2026 (Estimated)Latest FDMT, SRPT, VCEL, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026FDMT4D Molecular Therapeutics-$0.97-$1.01-$0.04-$1.01$2.59 million$3.05 million5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million3/18/2026Q4 2025FDMT4D Molecular Therapeutics-$0.53$0.43+$0.96$0.43$30.86 million$85.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A9.349.34SNDXSyndax Pharmaceuticals8.265.475.06SRPTSarepta Therapeutics0.564.632.62VCELVericelN/A5.184.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%SNDXSyndax PharmaceuticalsN/ASRPTSarepta Therapeutics86.68%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics7.90%SNDXSyndax Pharmaceuticals4.10%SRPTSarepta Therapeutics6.90%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12052.28 million48.15 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableVCELVericel30051.07 million47.19 millionOptionableFDMT, SRPT, VCEL, and SNDX HeadlinesRecent News About These CompaniesVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 23, 2026 | americanbankingnews.comSummit Creek Advisors LLC Reduces Stock Position in Vericel Corporation $VCELMay 21, 2026 | marketbeat.comVericel Lifts 2026 Outlook After Standout QuarterMay 19, 2026 | tipranks.comVericel Corporation $VCEL Stock Position Reduced by Truist Financial CorpMay 18, 2026 | marketbeat.comWhat is HC Wainwright's Estimate for Vericel Q4 Earnings?May 11, 2026 | marketbeat.comVericel Corporation 2026 Q1 - Results - Earnings Call PresentationMay 9, 2026 | seekingalpha.comAnalysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter ReportMay 9, 2026 | finance.yahoo.comVericel (VCEL) Q1 2026 Earnings TranscriptMay 9, 2026 | finance.yahoo.comVericel Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comVericel Earnings Call Signals Accelerating Growth and MarginsMay 8, 2026 | tipranks.comVericel (NASDAQ:VCEL) Trading Down 9.1% - What's Next?May 8, 2026 | marketbeat.comVericel Corporation (VCEL) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comVericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPSMay 7, 2026 | marketbeat.comVericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue EstimatesMay 7, 2026 | zacks.comVericel (NASDAQ:VCEL) Shares Gap Up on Strong EarningsMay 7, 2026 | marketbeat.comVericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 MillionMay 7, 2026 | quiverquant.comQVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceMay 7, 2026 | globenewswire.comVericel Q1 2026 earnings previewMay 7, 2026 | msn.comWall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a BetMay 4, 2026 | zacks.comVericel Shareholders Reaffirm Board, Pay Plan, AuditorMay 1, 2026 | tipranks.comConestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCELMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFDMT, SRPT, VCEL, and SNDX Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$8.97 +0.12 (+1.36%) Closing price 04:00 PM EasternExtended Trading$8.74 -0.23 (-2.56%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Syndax Pharmaceuticals NASDAQ:SNDX$19.75 +0.14 (+0.71%) As of 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$17.30 +0.62 (+3.72%) Closing price 04:00 PM EasternExtended Trading$17.26 -0.05 (-0.26%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Vericel NASDAQ:VCEL$34.24 -0.03 (-0.09%) Closing price 04:00 PM EasternExtended Trading$34.22 -0.02 (-0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake and the Snowballing Impact of its AI Flywheel IREN Is Flipping the Switch from Bitcoin to AI 3 Stocks Rallying on Micron's Price Boost: Substance or Hype? This Quantum Computing Stock May Be Closer to a Breakout Than You Think Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It AI’s Biggest Bottleneck Could Make These 2 Stocks Soar If the Market Rally Stalls, This ETF Can Insulate Portfolios RTX Is Set to Revolutionize Munitions Manufacturing Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
